$SCNX News

Scienture Holdings Stock Jumps Over 20% Pre-Market: Here's Why

SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY™ (naloxone hydrochloride) to Wholesalers

Scienture To Begin Shiptments Of REZENOPY Nasal Spray 10mg To U.S. Pharmaceutical Wholesalers Later This Month

SCIENTURE Expands Arbli™ Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide

Scienture Announces Progress Towards Commercialization Of Its Arbli Oral Suspension Including Expanded Payor Coverage, Broader Pharmacy Access And New Channel Partnerships

SCIENTURE Secures Formulary Coverage for REZENOPY™ with a Large National Health Plan and Expands Commercial Team

EXCLUSIVE: Scienture Expands Coverage For Opioid Overdose Treatment Ahead Of Commercial Launch

EXCLUSIVE: Scienture Expands Coverage For Opioid Overdose Treatment Ahead Of Commercial Launch

EXCLUSIVE: SCIENTURE Secures Formulary Coverage For REZENOPY; Commercial Launch Planned For Mid-July

SCIENTURE to Present at The Small Cap Showcase & WTR Insights on June 9, 2026, in NYC

SCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041

Scienture Eric Sherb Resigns As CFO Effective May 26, 2026; Narasimhan Mani Appointed As Interim CFO Effective May 26, 2026

SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion

Scienture Holdings Q1 EPS $(0.08) Beats $(0.22) Estimate, Sales $56.325K Up From $10.258K YoY

Scienture Secures $11.0 Million in Non-Dilutive Debt Financing to Accelerate Growth of Approved Product Portfolio and Advancement of R&D Pipeline

SCIENTURE HOLDINGS Secures $11M In Non-Dilutive Debt Financing Through Note Purchase Agreement With Institutional Investor

SCIENTURE Announces Third Patent Grant for ARBLI™ (losartan potassium) Oral Suspension, Strengthening Long-Term Market Exclusivity Through 2041

USPTO Issued SCIENTURE HOLDINGS U.S. Patent No. 12,605,365, Titled "Losartan Liquid Formulations and Methods of Use,"

Scienture Awarded $950K U.S. Department Of Veterans Affairs Pharmaceutical Supply Contract, Pharmaceutical Preparation Manufacturing

Scienture Holdings shares are trading higher after the company announced it has been granted 180-day extension by the Nasdaq to regain compliance.